Argus analyst John Staszak upgraded Kimberly-Clark Corporation (KMB) to a Buy rating with a $120 price target, citing better-than-expected Q3 earnings and plans to acquire Kenvue. The acquisition of Kenvue, which owns major consumer health brands, is expected to strengthen KMB's position in resilient product categories, making it an appealing value pick for long-term investors. Kimberly-Clark generates most of its revenue through direct sales to retailers and has a broad global footprint serving both consumer and professional markets.

<p>Argus 分析師 John Staszak 將金佰利公司（Kimberly-Clark Corporation，KMB）的評級上調至買入，目標價為 120 美元，理由是其第三季度業績好於預期，並計劃收購 Kenvue。收購擁有主要消費健康品牌的 Kenvue 預計將增強 KMB 在抗壓產品類別中的地位，使其成為長期投資者的有吸引力的價值選擇。金佰利大部分收入來自對零售商的直接銷售，並在服務消費者和專業市場方面擁有廣泛的全球佈局</p>

分析師指出，Kimberly Clark (KMB) 在加深其消費者健康領域的佈局後，前景更加樂觀